$ELDN
Eledon Pharmaceuticals, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024125622 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.990M
YoY Change 22.02%
% of Gross Profit
Research & Development $16.52M
YoY Change 108.3%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $20.51M
YoY Change 83.16%
Operating Profit -$20.51M
YoY Change 83.16%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.042M
YoY Change 22.73%
Pretax Income $76.97M
YoY Change -843.68%
Income Tax
% Of Pretax Income
Net Earnings $77.00M
YoY Change -844.03%
Net Earnings / Revenue
Basic Earnings Per Share $1.05
Diluted Earnings Per Share -$0.32
COMMON SHARES
Basic Shares Outstanding 59.74M 39.66M
Diluted Shares Outstanding 55.48M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $78.19M
YoY Change 31.19%
Cash & Equivalents $6.751M
Short-Term Investments $71.44M
Other Short-Term Assets $442.0K
YoY Change 391.11%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $81.51M
YoY Change 29.4%
LONG-TERM ASSETS
Property, Plant & Equipment $471.0K
YoY Change -5.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $210.0K
YoY Change -9.87%
Total Long-Term Assets $33.07M
YoY Change -0.03%
TOTAL ASSETS
Total Short-Term Assets $81.51M
Total Long-Term Assets $33.07M
Total Assets $114.6M
YoY Change 19.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.860M
YoY Change 1160.22%
Accrued Expenses $6.629M
YoY Change 176.21%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.49M
YoY Change 330.8%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $24.28M
YoY Change 24177.0%
Total Long-Term Liabilities $24.28M
YoY Change 24177.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.49M
Total Long-Term Liabilities $24.28M
Total Liabilities $38.52M
YoY Change 713.65%
SHAREHOLDERS EQUITY
Retained Earnings -$311.0M
YoY Change 33.13%
Common Stock $386.9M
YoY Change 19.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $76.06M
YoY Change
Total Liabilities & Shareholders Equity $114.6M
YoY Change 19.26%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income $77.00M
YoY Change -844.03%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$11.77M
YoY Change -3.93%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$12.80M
YoY Change -48.85%
Cash From Investing Activities -$12.80M
YoY Change -48.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.283M
YoY Change
NET CHANGE
Cash From Operating Activities -11.77M
Cash From Investing Activities -12.80M
Cash From Financing Activities 5.283M
Net Change In Cash -19.29M
YoY Change -48.26%
FREE CASH FLOW
Cash From Operating Activities -$11.77M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
76971000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9906000
us-gaap Net Income Loss
NetIncomeLoss
8433000
us-gaap Net Income Loss
NetIncomeLoss
-86438000
CY2024Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
22542000
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
2882000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
54429000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9906000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
5551000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-86438000
CY2024Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
22542000
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
2882000
CY2024Q3 eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds Net Of Tax
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceedsNetOfTax
-94475000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds Net Of Tax
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceedsNetOfTax
-69519000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17504000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9906000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-61086000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-86438000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51945920
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29974400
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41443049
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22813085
CY2024Q3 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
3532422000
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
1663697000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55478342
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29974400
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43106746
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22813085
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.05
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.79
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.79
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
41472694
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
40177333
dei Entity Central Index Key
EntityCentralIndexKey
0001404281
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Earnings Per Share Diluted Convertible Security Method Extensible Enumeration
EarningsPerShareDilutedConvertibleSecurityMethodExtensibleEnumeration
http://www.eledon.com/20240930#CommonStockWarrantsMember
us-gaap Earnings Per Share Diluted Convertible Security Method Extensible Enumeration
EarningsPerShareDilutedConvertibleSecurityMethodExtensibleEnumeration
http://www.eledon.com/20240930#CommonStockWarrantsMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36620
dei Entity Registrant Name
EntityRegistrantName
ELEDON PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-1000967
dei Entity Address Address Line1
EntityAddressAddressLine1
19800 MacArthur Blvd
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 250
dei Entity Address City Or Town
EntityAddressCityOrTown
Irvine
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92612
dei City Area Code
CityAreaCode
(949)
dei Local Phone Number
LocalPhoneNumber
238-8090
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
ELDN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59739275
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6751000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4612000
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
71440000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
46490000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3318000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5027000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
81509000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
56129000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
471000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
365000
CY2024Q3 eldn In Process Research And Development
InProcessResearchAndDevelopment
32386000
CY2023Q4 eldn In Process Research And Development
InProcessResearchAndDevelopment
32386000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
210000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
186000
CY2024Q3 us-gaap Assets
Assets
114576000
CY2023Q4 us-gaap Assets
Assets
89066000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5860000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
967000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
186000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
383000
CY2024Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6443000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2545000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12489000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3895000
CY2024Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1752000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1752000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
315000
CY2024Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
23962000
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
76211000
CY2024Q3 us-gaap Liabilities
Liabilities
38518000
CY2023Q4 us-gaap Liabilities
Liabilities
81858000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41183102
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41183102
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24213130
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24213130
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
41000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
24000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
386884000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
326586000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
102000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-310969000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-319402000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
76058000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
7208000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
114576000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
89066000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16520000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7931000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34036000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23245000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3990000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3267000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11845000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9417000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
20510000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
11198000
us-gaap Operating Expenses
OperatingExpenses
45881000
us-gaap Operating Expenses
OperatingExpenses
32662000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-20510000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11198000
us-gaap Operating Income Loss
OperatingIncomeLoss
-45881000
us-gaap Operating Income Loss
OperatingIncomeLoss
-32662000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1042000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
849000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2485000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1962000
CY2024Q3 eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
-96439000
CY2023Q3 eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
-443000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
-51829000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
55738000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
76971000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9906000
us-gaap Net Income Loss
NetIncomeLoss
8433000
us-gaap Net Income Loss
NetIncomeLoss
-86438000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
54429000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9906000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
5551000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-86438000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.05
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.79
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51945920
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29974400
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41443049
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22813085
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17504000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9906000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-61086000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-86438000
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.79
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55478342
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29974400
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43106746
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22813085
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
76971000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9906000
us-gaap Net Income Loss
NetIncomeLoss
8433000
us-gaap Net Income Loss
NetIncomeLoss
-86438000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
102000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
102000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
77073000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9906000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
8535000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-86438000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
7208000
CY2024Q1 eldn Issuance Of Common Stock In Connection With Exercise Of Pre Funded Warrants Value
IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue
1000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1694000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-23631000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-14728000
CY2024Q2 eldn Issuance Of Common Stock In Connection With Private Investment In Public Equity Transaction Net Of Issuance Costs Value
IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue
48070000
CY2024Q2 eldn Issuance Of Common Stock In Connection With Exercise Of Pre Funded Warrants Value
IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue
1000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3063000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-44907000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-8501000
CY2024Q3 eldn Issuance Of Common Stock In Connection With Private Investment In Public Equity Transaction Net Of Issuance Costs Value
IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue
5703000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1783000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
102000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
76971000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
76058000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
84183000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1381000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10772000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
74792000
CY2023Q2 eldn Issuance Of Common Stock In Connection With Private Investment In Public Equity Transaction Net Of Issuance Costs Value
IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue
33017000
CY2023Q2 eldn Issuance Of Common Stock In Connection With Conversion Of X1 Non Voting Convertible Preferred Stock Value
IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue
-1000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1720000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-65760000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
43768000
CY2023Q3 eldn Issuance Of Common Stock In Connection With Exercise Of Pre Funded Warrants Value
IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue
1000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1734000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9906000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
35597000
us-gaap Net Income Loss
NetIncomeLoss
8433000
us-gaap Net Income Loss
NetIncomeLoss
-86438000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
10000
eldn Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
271000
eldn Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
280000
eldn Accretion On Investment Discounts
AccretionOnInvestmentDiscounts
-1916000
eldn Accretion On Investment Discounts
AccretionOnInvestmentDiscounts
-579000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6540000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4835000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
-51829000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
55738000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1685000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
356000
eldn Accounts Payable Accrued Expenses And Other Liabilities
AccountsPayableAccruedExpensesAndOtherLiabilities
8791000
eldn Accounts Payable Accrued Expenses And Other Liabilities
AccountsPayableAccruedExpensesAndOtherLiabilities
-3609000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-249000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-267000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28284000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30396000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
83350000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
60363000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
60418000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
5000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-22932000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-55363000
eldn Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet
53355000
eldn Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet
33017000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
53355000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
33017000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2139000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-52742000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4612000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56409000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6751000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3667000
eldn Common Stock Exchanged For X And X One Non Voting Convertible Preferred Stock
CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock
1000
eldn Unrealized Gain On Available For Sale Securities
UnrealizedGainOnAvailableForSaleSecurities
102000
eldn Increase Decrease In Operating Lease Asset And Liability Due To New Lease
IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToNewLease
377000
eldn Settlement Of Warrant Liability Into Common Stock Due To Exercise
SettlementOfWarrantLiabilityIntoCommonStockDueToExercise
420000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
77000000
us-gaap Net Income Loss
NetIncomeLoss
8400000
CY2024Q3 eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
-96400000
CY2024Q3 eldn Net Income Losses Excluding Gain Of Change In Fair Value Of Warrant
NetIncomeLossesExcludingGainOfChangeInFairValueOfWarrant
-19500000
eldn Net Income Losses Excluding Gain Of Change In Fair Value Of Warrant
NetIncomeLossesExcludingGainOfChangeInFairValueOfWarrant
-43400000
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
78200000
CY2024Q3 eldn Working Capital
WorkingCapital
69000000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-311000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to stock-based compensation expense, warrant liabilities, the fair value of right-of-use assets and liabilities, accruals for liabilities, impairment of long-lived assets, and other matters that affect the consolidated financial statements and related disclosures. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ materially from those estimates under different assumptions or conditions and the differences may be material to the consolidated financial statements.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to significant concentration of credit risk consists of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured institutions in excess of federally insured limits and invests in short-term investments with the primary objective of seeking to preserve principal, achieve liquidity requirements and safeguard invested funds. We believe that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held and the nature, including the credit ratings, of our cash equivalents and short-term investments, but we have not eliminated all credit risk.</span></p>
eldn Cash Cash Equivalents And Restricted Cash Maturity Period
CashCashEquivalentsAndRestrictedCashMaturityPeriod
three months or less
CY2023Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
55738000
CY2023Q3 us-gaap Liabilities
Liabilities
60472000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
24000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
324876000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-289303000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
35597000
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
71338000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
105000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
71440000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
46490000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
46490000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds Includes Reversal
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceedsIncludesReversal
58700000
CY2024Q3 eldn Prepaid Clinical Expense
PrepaidClinicalExpense
2526000
CY2023Q4 eldn Prepaid Clinical Expense
PrepaidClinicalExpense
4128000
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
87000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
624000
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
263000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
185000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
442000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
90000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3318000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5027000
CY2024Q3 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
2062000
CY2023Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
2003000
CY2024Q3 eldn Accrued Clinical Current
AccruedClinicalCurrent
3798000
CY2023Q4 eldn Accrued Clinical Current
AccruedClinicalCurrent
451000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
475000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
47000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
108000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
44000
CY2024Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6443000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2545000
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
eldn Lessee Operating Lease Remaining Term Of Contract
LesseeOperatingLeaseRemainingTermOfContract
P3Y
CY2024Q3 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
0
us-gaap Operating Lease Cost
OperatingLeaseCost
306000
us-gaap Operating Lease Cost
OperatingLeaseCost
300000
us-gaap Operating Lease Payments
OperatingLeasePayments
272000
us-gaap Operating Lease Payments
OperatingLeasePayments
279000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M21D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y2M12D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0960
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0248
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
83000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
191000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
197000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
100000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
571000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
70000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
501000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
186000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
315000
CY2024Q3 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0358
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0384
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0388
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9346
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9839
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8908
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9428
CY2024Q3 us-gaap Share Price
SharePrice
2.49
CY2023Q4 us-gaap Share Price
SharePrice
1.8
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1783000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1734000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6540000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4835000
CY2023Q3 eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
-443000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
55738000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9906000
us-gaap Net Income Loss
NetIncomeLoss
-86438000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.79
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
84183000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1381000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10772000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
74792000
CY2023Q2 eldn Issuance Of Common Stock In Connection With Private Investment In Public Equity Transaction Net Of Issuance Costs Value
IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue
33017000
CY2023Q2 eldn Issuance Of Common Stock In Connection With Conversion Of X1 Non Voting Convertible Preferred Stock Value
IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue
-1000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1720000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-65760000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
43768000
CY2023Q3 eldn Issuance Of Common Stock In Connection With Exercise Of Pre Funded Warrants Value
IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue
1000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1734000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9906000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
35597000
us-gaap Net Income Loss
NetIncomeLoss
-86438000
eldn Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds
ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds
55738000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30396000
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-125622-index-headers.html Edgar Link pending
0000950170-24-125622-index.html Edgar Link pending
0000950170-24-125622.txt Edgar Link pending
0000950170-24-125622-xbrl.zip Edgar Link pending
eldn-20240930.htm Edgar Link pending
eldn-20240930.xsd Edgar Link pending
eldn-ex31_1.htm Edgar Link pending
eldn-ex31_2.htm Edgar Link pending
eldn-ex32_1.htm Edgar Link pending
eldn-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
eldn-20240930_htm.xml Edgar Link completed
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable